Novartis COVID-19 Therapy Could Overcome Escape Variant Problem
Protein Therapeutic Enters Pivotal Trial
Executive Summary
The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.
You may also be interested in...
J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.
J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.
Novartis and Molecular Partners’ Ensovibep Flunks In ACTIV-3 In Hospitalized COVID-19 Patients
Ensovibep failed to meet thresholds for continued enrollment in the large NIH Phase III trial, forcing Novartis and Molecular to home in on the early COVID-19 setting instead.